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Technetium-99m isonitrile is a new myocardial perfusion 
imaging agent that accumulates according to the distrihu- 
tion of myocardial blood flow. However, unlike thallium- 
201, it does not redistribute over time. This imaging agent 
was used with serial quantitative planar imaging to assess 
the initial risk area of infarction, its change over time and 
the relation to infarct-related artery patency in 30 patients 
with a first acute myocardial infarction. Twenty-three of 30 
patients were treated with recombinant tissue-type plasmin- 
ogen activator (r&PA) within 4 h after the onset of chest 
pain. Seven patients were treated in the conventional 
manner without thrombolytic therapy. Technetium-99m 
isonitrile was injected before or at the initiation of throm- 
bolytic therapy, and imaging was performed several hours 
later. These initial images demonstrated the area at risk. 
Repeat imaging was performed 18 to 48 h later and at 6 to 
14 days after the onset of myocardial infarction to visualize 
the ultimate extent of infarction. 
The initial area at risk varied greatly (range defect 
integral 2 to 61) both in patients treated with r&PA and in 
those who received conventional treatment. For the total 
group, the initial imaging defect decreased in size in 20 
patients and was unchanged or larger in 10 patients. 
Patients with a patent infarct-related artery had a signifi- 
cantly greater decrease in defect size than did patients with 
persistent coronary occlusion (-51 f 38% versus -1 + 
26%) p = 0.0001). All patients with a decrease in defect size 
>30% had a patent infarct-related artery. In 12 patients 
who also had predischarge quantitative exercise thallium- 
201 imaging, good agreement existed between the extent 
and severity of myocardial perfusion defect on the last 
technetium-99m isonitrile study before discharge and that 
noted on delayed thallium-201 imaging. 
It is concluded that serial planar technetium-99m isoni- 
trile myocardial imaging in patients with acute myocardial 
infarction undergoing thrombolytic therapy offers a new 
quantitative noninvasive approach for assessment of the 
initial risk zone as well as the success of reperfusion. 
(J Am Co11 Cardioll989;14:861-73) 
Intravenous thrombolytic therapy is now the preferred ther- 
apeutic approach in the initial hours of acute myocardial 
From the Cardiovascular Nuclear Imaging Laboratory, *Department of 
Diagnostic Radiology. Section of Cardiology and *Department of Internal 
Medicine, Yale University School of Medicine, New Haven, Connecticut; 
tDivision of Cardiovascular Disease and Internal Medicine, Mayo Clinic, 
Rochester, Minnesota and $Section of Cardiology, Department of Medicine, 
Baylor College of Medicine/The Methodist Hospital, Houston, Texas. This 
study was supported by TIM1 Contract No. I-HV-38017 and a grant from 
DuPont de Nemours & Co.. Inc., from the National Heart, Lung, and Blood 
Institute. Bethesda, Maryland. Diagnostic Imaging Division, North Billerica. 
Massachusetts. 
Manuscript received January 5, 1989: revised manuscript received March 
23, 1989, accepted April 20, 1989. 
Address for reprints: Ft?iIIS J. Th. Wackers, MD, Department of Diagnor- 
tic Radiology - TE-2, Yale University School of Medicine, 333 Cedar Street. 
New Haven. Conneclrcut 06510. 
infarction. Several trials in large numbers of patients have 
separately shown that early thrombolytic therapy may rees- 
tablish flow in the infarct-related artery (I-1 I), limit the 
extent of left ventricular dysfunction (5,12-22) and reduce 
both early and 1 year mortality (6-10,12.13,23-27). Depend- 
ing on the thrombolytic agent used. reperfusion will be 
induced to 50% to 80% of cases (3,4,11.22). However, 
despite initial successful reperfusion, the degree of myocar- 
dial salvage may be minimal and a substantial number of 
reperfused infarct-related vessels may reocclude during hos- 
pitalization (28.29). These clinical and therapeutic circum- 
stances have led to a need to define 1) whether reperfusion 
has occurred, 2) whether infarct-related artery patency has 
been maintained, and 3) the initial “risk zone” of hypoper- 
fusion and the extent to which this hypoperfusion regresses 
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or is modified with therapy. Such data may be related to the 
degree of myocardial salvage. 
Several clinical and noninvasive indicators of reperfusion 
have been proposed. These include a sudden decrease in 
chest pain, normalization of ST segment elevation and the 
appearance of “reperfusion arrhythmias” (3&35). How- 
ever, these variables generally appear to lack both sensitiv- 
ity and specificity (36). At present, probably the most 
reliable indicators of successful coronary artery reperfusion 
are early peaking of serum creatine kinase and early release 
of myoglobin (37-40). However, this approach does not 
provide anatomic insight concerning the initial risk area and 
degree of reperfusion. 
Recently, technetium-99m isonitrile, a new radioisotope- 
labeled myocardial perfusion agent with unique biologic 
properties, has been introduced (41-43). This radiopharma- 
ceutical has potential for serial noninvasive imaging and 
quantification of the initial area at risk as well as the 
presence of reperfusion in patients with acute infarction 
undergoing thrombolytic therapy (44-47). After intravenous 
injection, technetium-99m isonitrile accumulates in the myo- 
cardium predominantly according to myocardial blood flow 
in a manner comparable with that of thallium-201 (48-50). 
However, unlike thallium-201, this radiopharmaceutical 
does not show significant subsequent redistribution (51-54). 
Rather, it remains stably bound to either myocardial cyto- 
solic or mitochondrial proteins (51,55). Consequently, the 
myocardial perfusion pattern at the time of injection remains 
reflected in the technetium-99m isonitrile myocardial scinti- 
graphic image for several hours thereafter. This unique 
characteristic was utilized in the present study. 
Our purpose was to assess the efficacy of this new 
imaging technique for evaluating patients undergoing throm- 
bolytic therapy for acute myocardial infarction. Serial quan- 
titative planar imaging was performed. An initial study was 
obtained after injection of technetium-99m isonitrile before 
thrombolysis, with imaging performed several hours later. 
The perfusion defect in this study defined the initial risk 
zone. Subsequent comparative studies obtained after repeat 
injections 18 to 48 h or 6 to 14 days later, or both, identified 
a zone of hypoperfusion representing the final infarct. Com- 
parison of the latter images with those obtained initially 
allowed definition of the extent of improvement of myocar- 
dial perfusion. 
Methods 
Study patients. A total of 30 nonconsecutive patients 
with their first acute myocardial infarction had technetium- 
99m isonitrile studies. The patients were selected on the 
basis of the availability of this new radiopharmaceutical, 
laboratory logistics and willingness to participate. Studies 
were obtained from June 1987 to June 1988. There were 24 
men and 6 women with a mean age of 58 2 9 years (range 40 
to 70). Twelve patients had anterior wall infarction and 18 
had inferior wall infarction defined by conventional electro- 
cardiographic (ECG) criteria (56). In all patients, acute 
myocardial infarction was documented by serial creatine 
kinase determinations. Thirteen patients were studied at 
Yale-New Haven Hospital,* 12 at the Mayo Clinic? and 5 at 
Baylor College of Medicine.? Twenty-three patients re- 
ceived thrombolytic therapy with recombinant tissue-type 
plasminogen activator (r&PA), 21 as participants in the phase 
II Thrombolysis in Myocardial Infarction (TIMI) Trial. 
Seven patients had conventional nonthrombolytic treatment 
for myocardial infarction. The latter group is included to 
provide some comparative natural history data. However, 
because of the relatively small number, this group should not 
be considered a control group. Five additional patients had 
initial technetium-99m isonitrile studies (after injection in the 
emergency room), but had no follow-up studies or their 
technetium-99m isonitrile images were technically inade- 
quate for quantitation. These five patients were excluded 
from analysis; they were not clinically or angiographically 
different from the study patients. 
Patients were considered candidates for thrombolytic 
therapy if they met previously published inclusion criteria 
(57). Briefly, these criteria included 1) chest pain persisting 
for >30 min but present for <4 h since onset, and 2) ~1 mm 
of ST segment elevation in two or more ECG leads. In 
addition, only patients with a first myocardial infarction 
were considered. This criterion was established to exclude 
any interpretive problems that might result from multiple 
perfusion defects if patients with a prior infarction were 
included. The exclusion criteria for rt-PA administration 
have also been published previously (57). The patients 
receiving conventional treatment for infarction were se- 
lected according to the following criteria: 1) contraindication 
for rt-PA administration, 2) onset of chest pain >4 h before 
admission (but I 12 h), 3) 2 1 mm of ST segment elevation in 
two or more ECG leads, and 4) first myocardial infarction. 
The protocol was approved by each institutional review 
board (1987), and informed consent was obtained from all 
patients. 
Additional treatment. Patients treated with rt-PA re- 
ceived continuous intravenous heparin infusion for 5 days 
after thrombolytic therapy. In addition, they received 80 
mglday of aspirin, which was increased to 325 mglday when 
heparin was discontinued. Patients undergoing thrombolysis 
without contraindications to beta-adrenergic blocker therapy 
also were randomized to immediate beta-blocker therapy 
versus beta-blocker therapy starting at day 6. Five patients 
included in the present study received immediate beta- 
blocker therapy. Calcium channel blocking agents were 
*One patient has been reported earlier (44). tTen of the patients at the 
Mayo Clinic and Baylor College of Medicine also had SPECT imaging. These 
results are to be reported separately (101). 
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routinely prescribed after percutaneous transluminal coro- 
nary angioplasty. Conventional treatment for acute myocar- 
dial infarction consisted of morphine sulfate for relief of 
pain, prophylactic lidocaine infusion, intravenous nitroglyc- 
erin and vasodilator or vasopressor therapy as clinically 
indicated. 
Percutaneous transluminal coronary angioplasty. After 
initial treatment with intravenous rt-PA, patients were ran- 
domized to coronary angioplasty at 18 to 48 h versus no 
coronary angioplasty according to the TIM1 protocol (57). In 
the latter group of patients, angioplasty was performed only 
for clinical reasons such as evidence of recurrent ischemia. 
In the present study, angioplasty was performed in a total of 
14 patients (13 treated with rt-PA, 1 treated conventionally). 
In six patients, angioplasty involved the left anterior de- 
scending coronary artery, in seven the right coronary artery 
and in one the left circumflex coronary artery. Coronary 
angioplasty was successful (an absolute reduction of 20% of 
luminal narrowing and a residual stenosis ~60% by visual 
estimate) in 13 of the 14 patients. In six patients, it was 
performed during the time interval between technetium-99m 
isonitrile study 1 and study 2 (mean 9 ? 6 h after acute 
infarction). In eight patients, angioplasty was performed 
after study 2. 
Radiopharmaceutical preparation. The radiopharmaceu- 
tical is a lyophilized formulation containing 2-methoxy- 
isobutyl-isonitrile. Technetium-99m isonitrile is prepared by 
adding sodium pertechnetate-technetium-99m to the vial and 
boiling for 10 min. For the present study, the radiopharma- 
ceutical was prepared each morning and was readily avail- 
able throughout the day. This agent should be used within 8 
h of preparation. 
Serial imaging protocol. Patients who were identified in 
the emergency room as candidates for thrombolytic therapy 
and consented to the present protocol received 25 to 30 mCi 
of technetium-99m isonitrile intravenously as soon as possi- 
ble before or at the inception of the intravenous administra- 
tion of 100 mg of rt-PA (Genentech) over 6 h. Subsequently, 
the patients were transferred to the coronary care unit and 
treated according to a standardized clinical protocol. As 
soon as patients were clinically stable and gamma camera 
imaging would not interfere with the patients’ treatment, 
planar myocardial imaging (study 1) was performed. Three 
views were obtained: left anterior oblique, left lateral and 
anterior. Each image was acquired for 5 min, accumulating 
approximately 2 million counts per view. Patients receiving 
conventional therapy received technetium-99m isonitrile as 
soon as possible after admission. 
Study 2 was obtained after a new injection of 25 to 30 mCi 
of technetium-99m isonitrile 18 to 48 h later and use of the 
same imaging technique. Study 3 was obtained in a compa- 
rable manner at the time of hospital discharge (day 6 to 14). 
In addition, a subgroup of patients also underwent rest 
equilibrium radionuclide angiocardiography (n = 16) and 
quantitative planar thallium-201 submaximal exercise imag- 
ing (n = 12) before hospital discharge. These studies were 
obtained in multiple views according to standardized tech- 
niques (58, 59). 
The delayed thallium-201 images (showing myocardial 
perfusion at rest) were compared on a segment to segment 
basis with the most recent technetium-99m isonitrile images 
(study 3 in eight patients, study 2 in four patterns) for 
comparison of regional myocardial uptake. 
Perfusion status of the infarct-related artery. The status of 
the infarct-related artery was verified by coronary angiogra- 
phy in 27 of the 30 patients. The TIMI angiographic scale 
was employed to define the presence, absence and degree of 
reperfusion (3). Angiographic reperfusion of the infarct- 
related artery in the present study was defined as TIMI grade 
2or3. 
Twenty-three patients underwent coronary angiography 
within the first 5 hospital days (in IO patients within the first 
24 h), and 4 had coronary angiography within 2 weeks of 
infarction. Three patients did not undergo coronary angiog- 
raphy; of these three patients, one died on the 4th hospital 
day and had an occluded infarct-related artery documented 
by postmortem examination. In the other two patients, the 
status of the infarct-related artery was inferred from the 
predischarge thallium-201 exercise test. One patient had a 
large fixed thallium-201 defect and was categorized as having 
an “occluded infarct-related artery.” The other patient had 
a single large reversible thallium-201 defect in the infarct 
zone at discharge and was categorized as having an “open 
infarct-related artery.” 
Of the 27patients who underwent coronary angiography, 
13 had single vessel, 6 had double vessel and 9 had triple 
vessel coronary disease. In seven patients, collateral vessels 
to the infarct-related artery were present. 
Quantitation of defect size. All studies were stored on 
either floppy disk or magnetic tape and mailed to Yale 
University for uniform processing and quantification. After 
transcription to a PCS 512 computer, 128 X 128 static images 
were analyzed quantitatively. The size of the myocardial 
perfusion defect was quantitated with use of a previously 
validated program (60), initially designed for thallium-201 
scintigraphy and subsequently modified for isonitrile imaging 
(60-62). After modified interpolative background subtrac- 
tion, circumferential count distribution profiles were gener- 
ated, displaying mean count density in 36 segments. The 
segment with the highest mean count density was designated 
as lOO%, and all remaining segments were displayed relative 
to this maximal value. This allowed comparison of the 
relative distribution of technetium-99m-isonitrile uptake in 
serial studies. 
The size of the myocardial perfusion defect was defined 
by integrating the hypoperfused area under the lower limit of 
normal curve (mean - 2 SD, derived from a data base of rest 
technetium-99m isonitrile images in 17 normal subjects with 
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Figure 1. This schematic diagram (top) shows an apical-septal defect 
(A) on a left anterior oblique (LAO) image. The left ventricle (A t 
B) is divided into 36 IO” segments, and a circumferential distribution 
profile (black dots) (middle) is generated by plotting the mean count 
density of each segment. The segment with the highest mean count 
density is assigned IO%, and the other segments are plotted as a 
percent of this maximal value. The profile is superimposed on a 
curve (solid line) indicating the lower limit of normal (mean - 2 SD) 
distribution of technetium-99m isonitrile. The defect integral is 
calculated as indicated (bottom). The extent of the defect is reflected 
by the number of segments below the normal limit. The severity of 
the defect is reflected by the depth below the normal limit. 
~3% likelihood of coronary artery disease). The hypoper- 
fused area was expressed as a proportion (X 100) of the total 
potentially visualized normal myocardium (Fig. 1). This 
value is unitless and reflects both the extent and severity of 
the myocardial perfusion defect. Total defect size in a three 
view study was defined as the sum of defects on three views. 
In comparison with visual analysis, a defect with a total size 
of 1 to 5 can be categorized as “small,” 5 to 10 as 
“moderate” and >lO as “large.” 
Statistical analysis. Data were expressed as mean values 
2 SD. Differences between paired data were analyzed by 
two-tailed paired t test, differences between groups by 
unpaired t test and differences in serial data by analysis of 
variance. Frequency data were analyzed by the Fisher exact 
test. Nonparametric analysis (Wilcoxon rank sum test) was 
used for paired and nonpaired data that were not normally 
distributed. Correlations among paired data were deter- 
mined by linear regression analysis. A p value co.05 was 
considered to be statistically significant. 
Results 
The relative change in defect size on serial images 
(expressed us a percent) was defined as: 
Defect 1 - Defect 2 x loo 
Defect 1 
Feasibility of serial imaging. The time interval between 
notification of the investigators and administration of the 
radiopharmaceutical in the emergency room was not >20 
min in any patient, which was well within the time required 
for preparing and starting infusion of rt-PA. In no instance 
was thrombolytic therapy delayed to inject the radiopharma- 
ceutical. 
The interobserver variability of the quantitation of defect The median time of injection of technetium99m isonitrile 
size has been previously evaluated in our laboratory by after the onset of chest pain was 120 min in r&PA-treated 
repeat processing of 45 studies by six experienced operators. patients and 255 min in patients receiving conventional 
The mean absolute interobserver variability was 2.0 ? 0.3. treatment. The median time between the administration of 
Only absolute changes >3 (mean + 2 SD) were considered to technetium-99m isonitrile and the start of rt-PA infusion was 
be significant. A difference of <3 between two measure- 
ments was, therefore, considered no change. 
Comparison of segmental defect size on technetium-99m 
isonitrile and thallium-201 images. For the purpose of com- 
paring segmental defect size on technetium-99m isonitrile 
and thallium-201 images, the circumferential profiles were 
subdivided into 5 segments on each view, totaling 15 seg- 
ments per study. In the left anterior oblique view, these 
segments were: basal septal, inferoseptal, apical, inferolat- 
eral, posterolateral; in the anterior view: anterobasal, an- 
terolateral, apical, inferoseptal, posteroseptal; and in the left 
lateral view: anterobasal, anterior, apical, inferior, infero- 
posterior. A segment was considered abnormal if the seg- 
mental defect integral was ~“1.” 
The segmental defect size on the last technetium-99m 
isonitrile image after thrombolysis was compared with seg- 
mental defect size in the corresponding segment on the 2 h 
delayed thallium-201 images in 12 patients who had predis- 
charge exercise imaging. No 24 h redistribution images were 
obtained. The defect on the last technetium-99m isonitrile 
image and on the corresponding delayed thallium-201 image 
is presumed to approximate the extent of the ultimate 
infarction. Segmental abnormalities were compared in the 
following defect integral categories: 0, 1 to 3,4 to 6 and 27. 
These categories were chosen arbitrarily to represent: no 
defect and small, medium or large defect, respectively. On 
the other hand, normal segmental thallium-201 uptake was 
considered to be evidence of viable myocardium in that 
particular segment. 
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Figure 2. Initial risk zone size in 23 patients treated with recombi- 
nant tissue-type plasminogen activator @t-PA) and 7 patients treated 
conventionally (Conv.Rx). The large bisected open diamonds indi- 
cate mean values. 
15 min in 21 of the 23 patients; however, in 2 patients, the 
agent was administered 10 min after the start of rt-PA 
infusion. Of 30 patients who had studies 1 and 2, 20 patients 
(17 treated with r&PA, 3 treated conventionally) also had 
predischarge study 3. 
Early serial technetium-99m isonitrile imaging (studies 1 
and 2). All 30 patients had a myocardial perfusion defect on 
study 1; this represents the presumed risk zone. In all 
patients, the scintigraphic location of the perfusion defect 
agreed with the ECG infarct location: 12 patients had an 
anterior perfusion defect and 18 had an inferoposterior 
perfusion defect. The size of risk zone (that is, perfusion 
defect integral) varied greatly and ranged from 4 to 61 in 
t-t-PA-treated patients and from 2 to 41 in the patients with 
conventional treatment (Fig. 2). There was no apparent 
relation between the number of diseased coronary arteries, 
the presence of collateral coronary circulation and the size of 
the zone at risk. The mean defect size in the 23 patients who 
received rt-PA was 24 + 18 compared with 20 ? 12 in 7 
patients with conventional treatment (p = NS). 
The mean dej&t size on study 2 in 23 rt-PA-treated 
patients was 18 + 16, significantly smaller (p < 0.001) 
compared with that on the acute study 1 (Fig. 3). Sixteen 
patients had a smaller defect and in 7 patients the defect was 
unchanged from that in the acute study. The mean relative 
change in defect size was -36 + 34%. 
In the patients with conventional treatment, the mean 
defect size on study 2 was 16 + 12 and was not different (p 
= NS) from that in the acute study 1. Four patients had a 
smaller defect, 2 had a defect that was unchanged and 1 
patient had a larger defect (+75%). The mean relutive 
change in defect size was - 14 2 49. 
Change in defect size and infarct-related artery status. 
Twenty patients (16 treated with rt-PA, of whom 4 also had 
coronary angioplasty, and 4 treated conventionally, of whom 
1 also had angioplasty) had a smaller total defect size on 
study 2. Of these 20, 15 had angiographic reperfusion (TIM1 
grade 2 or 3) of the infarct-related artery. In comparison, 10 
patients (7 treated with rt-PA, of whom 1 also had coronary 
angioplasty, and 3 treated conventionally) had unchunged or 
larger defect size on study 2, and only 3 of the 10 had an 
open infarct-related artery (p = 0.05). 
The meun change in defect size in 18 putients with an 
open infarct-related artery was -51 + 38% compared with 
- 1 2 26% in 12 patients with an occluded infarct-related 
artery (p = 0.0001). The change in defect size varied 
markedly in both groups (Fig. 4). However, a change in 
defect size >-30% best separated the two perfusion groups. 
A relative change in defect size between study 1 and 2 of 
> -30% concurred with an open infarct-related artery in all 
13 patients with such a change (positive accuracy 100%). A 
relative change in defect size of < - 30% concurred with an 
occluded artery in 11 of 17 patients with such a change 
(negative accuracy 70%). However, two of the latter patients 
had an open infarct-related artery after coronary angioplasty 
within 5 h after admission. Neither the prevalence of early 
creatine kinase peaking nor “clinical markers of reperfu- 
sion” were different (p = NS) among the patients with > or 
< -30% change in defect size. 
Serial changes in defect size (studies 1, 2 and 3). Twenty 
patients (17 treated with rt-PA, 3 treated conventionally) had 
three technetium-99m isonitrile studies. The mean defect 
integral was 23 ? lg on study 1, 18 t 16 on study 2 and 14 
:’ 13 on study 3 (p = NS) (Table 1). Of 17 patients treated 
with rt-PA, 9 had a smaller defect on study 2 compared with 
that on study 1; of these 9 patients, 5 had a further decrease. 
Of the remaining eight patients treated with rt-PA who 
initially had no change in defect size on study 2, five also had 
a smaller defect on study 3. Thus, 1 I of 17 patients ultimately 
had a decrease in defect size; in 10 patients, these changes 
continued or occurred relatively late after thrombolytic 
therapy. Successful coronary angioplasty could potentially 
explain the late improvement of myocardial perfusion in only 
three patients. 
Of 11 putients with an open infurct-related artery (either 
by thrombolysis or coronary angioplasty, or both), 8 ulti- 
mately had a decrease in defect size, whereas 3 of 6 patients 
with an occluded infarct-related artery had a decrease in 
defect size (p = NS). The serial changes in patients who had 
conventional treatment are shown in Table I. 
Relative distribution of technetium-99m isonitrile on last 
study after infarction and of thallium-201 on predischarge 
redistribution images. Comparison between thallium-201 up- 
take and technetium-99m isonitrile uptake was made only in 
those segments that were abnormal on technetium-99m 
isonitrile study 1. This was done to avoid contaminating the 
comparison with a relatively large number of normal seg- 
ments. Eighty segments were abnormal on technetium-99m 
isonitrile study 1; 58 of these were still abnormal on the last 
technetium-99m isonitrile study. On the delayed thallium- 
201 study. 53 of the 80 segments were abnormal. Of 22 
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Figure 3. Serial technetium-99m isonitrile imaging during thrombol- 
ysis in three representative patients in the anterior (ANT), left 
anterior oblique (LAO) and left lateral (LL) views. A, Patient with 
acute anteroseptal myocardial infarction and successful reperfusion 
of the infarct-related artery. The total three view defect size integral 
was 53 before thrombolytic treatment and 35 after thrombolysis, 
yielding a 33% change in defect size. B, Patient with acute infero- 
lateral myocardial infarction and successful reperfusion of the 
infarct-related artery. The total three view defect size was 49 before 
thrombolytic therapy and 28 after thrombolytic therapy, yielding a 
42% change in defect size. C, Patient with acute anteroseptal 
infarction and persistent coronary occlusion. The total three view 
defect size was 61 before thrombolytic therapy and 59 after throm- 
bolytic therapy, yielding an insignificant 3% difference in defect 
size. 
BEFORE 
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Figure 4. Change in perfusion defect size related to the status of the 
infarct-related artery. The percent change in individual patients 
between study 1 (before thromboiytic therapy) and study 2 (after 
thrombolytic therapy) is shown. The large bisected open diamonds 
indicate mean values. Abbreviations as in Figure 2. 
segments that became normal on the technetium-99m isoni- 
trile image, 16 were also normal on the thallium-201 image. 
The mean thallium-201 segmental defect size was 1.6 2 
1.8, and the mean technetium-99m isonitrile defect size was 
2.0 ? 2.3 (p = 0.02). The segmental defect size on the 
delayed thallium-201 images correlated well (r = 0.74, y = 
0.938x + 0.55) with segmental defect size on the last 
technetium-99m isonitrile study. Overall, there was agree- 
ment in defect size (or absence thereof) in 50 (63%) of the 80 
segments (Fig. 5 and 6). In 12 (15%) of the 80 segments, the 
size of the perfusion defect was less by technetium-99m 
isonitrile imaging, whereas in 18 segments (22%) technetium- 
99m isonitrile imaging indicated a more severe perfusion 
abnormality than was measured by thallium-201. No seg- 
mental defect ~4 on thallium-201 imaging was normal by 
Table 1. Serial Changes in Technetium-99m Isonitrile Defect 
Integral After Acute Myocardial Infarction in 20 Patients 
Change 
Treatment Study 1 vs. 2 Study 2 vs. 3 
rt-PA (n = 17) Smaller (n = 9) Smaller (n = 5) 
Unchanged (n = I) 
Larger (n = 3)* 
Unchanged (n = 8) Smaller (n = 5) 
Unchanged (n = 3) 
technetium-99m isonitrile imaging. Eleven segments in five 
patients were normal on thallium-201 imaging, but showed a 
small to moderate defect by technetium-99m isonitrile imag- 
ing. In two patients, the same segments were also normal on 
the immediate postexercise thallium-201 images. In three 
patients, these segments showed reversible thallium-201 
abnormalities after exercise. 
Left ventricular ejection fraction and defect size in rt- 
PA-treated patients. Sixteen patients treated with &PA had 
measurement of left ventricular ejection fraction by equilib- 
rium radionuclide angiography at hospital discharge. Left 
ventricular ejection fraction showed an inverse correlation 
with both the defect size on study 1 (r = -0.83, y = -0.5x 
+ 58.5) and study 2 (r = -0.76, y = -0.5x + 54.8) (Fig. 7). 
Predischarge ejection fraction did not correlate (r = 0.37) 
with the percent change in defect size on studies 1 and 2. 
Discussion 
Serial technetium-99m isonitrile imaging. This pilot study 
demonstrates the feasibility of performing serial quantitative 
planar technetium-99m isonitrile imaging in patients with 
acute myocardial infarction, starting with administration of 
the radiopharmaceutical in the emergency room before and 
without interfering with the initiation of thrombolytic ther- 
apy. In 16 of the 30 patients, imaging was performed at the 
bedside in the coronary care unit. Our observations indicate 
that the perfusion status of the infarct-related artery can be 
predicted from serial quantitative technetium-99m isonitrile 
imaging. A relative decrease of >30% in the size of the 
myocardial perfusion defect predicted patency of the infarct- 
related artery, and thus provided a direct measure of efficacy 
of treatment. The predictive accuracy of a change in defect 
size of <-30% for an occluded infarct-related artery was 
70%. However, the analysis may have been confounded by 
two patients with an open infarct-related vessel after coro- 
nary angioplasty shortly (~5 h) after admission. Despite the 
open infarct-related artery, they had little change in myocar- 
dial perfusion defect size. Patients with acute interventions 
such as coronary angioplasty should probably be subjects of 
a separate analysis in a future larger series of patients. We 
suggest that patients who demonstrate a ~-30% change in 
myocardial perfusion after thrombolytic therapy may not be 
optimal candidates for an aggressive interventional approach 
that includes coronary angioplasty. A relatively small 
change in myocardial perfusion would indicate a small, 
potentially salvageable area of myocardium, with attendant 
minimal anticipated benefits. This hypothesis should be 
tested in the future in a larger series of patients with varying 
degrees of change in myocardial perfusion defects. 
Conventional (n = 3) Smaller (n = 2) 
Larger (n = 1) 
Smaller (n = 1) 
Larger (n = I)t 
Unchaneed (n = 1) 
*Defect integral: study 3 = study I (n = 2); study 3 > study I (n = I): 
tdefect integral: study I > study 3 > study 2. &PA = recombinant tissue-type 
plasminogen activator: study 1 = admission: study 2 = I8 to 48 h; study 3 = 
Definition of risk zone. Our data also indicate that in 
patients with acute myocardial infarction, the initial area at 
risk may vary greatly and can be readily visualized and 
hospital discharge. quantitated by planar technetium-99m isonitrile scintigra- 
868 WACKERS ET AL. 
SERIAL ISONITRILE IMAGING IN THROMBOLYSIS 
JACC Vol. 14, No. 4 
October 1989:861-73 
TC- 99m ISONITRILE 
DAY 7 
III 7 
SEGMENTAL DEFECTSIZE 
phy. Experimental studies (6348) have shown that, because 
of marked and unpredictable variability of the risk zone, the 
ability to limit infarct size is best expressed relative to the 
initial area at risk. To date, clinical trials evaluating the 
efficacy of thrombolytic therapy have not directly consid- 
ered the initial area at risk as a relevant variable. Our 
observations confirm that patients with acute myocardial 
infarction constitute a heterogeneous group with a wide 
range of myocardium initially at risk and, hence, with 
variable potential for substantial myocardial salvage. This 
heterogeneity can be accounted for by quantitative techne- 
tium-99m isonitrile planar imaging. 
Figure 6. Contingency diagram comparing segmental defect size on 
thallium-201 redistribution images with corresponding segments on 
technetium (Tc)-99m isonitrile images after thrombolytic therapy. 
The comparison was performed only in the 80 segments that were 
abnormal on images obtained before thrombolytic therapy (see 
text). 
Tc-99m lsonitrile 
o l-3 4-6 %7 qefect size 
;; 
0 
(? E 1-3 
2 
54-6 
f 
s7 
Agreement 50/80 reqmantt(631) 
GCOBAL 
Figure 5. Comparison of segmental defect size on thal- 
lium-201 redistribution image (2.5 h after exercise) and 
technetium (Tc)-99m isonitrile image (day 7 after throm- 
bolysis) in a patient with successful reperfusion. The left 
anterior oblique (LAO) views are shown. The patient’s 
circumferential profiles are indicated by black dots (thal- 
lium-201 top, isonitrile bottom). The separately derived 
lower limit of normal distribution of thallium and tech- 
netium-99m isonitrile is indicated by the black curve. 
The defect size is indicated by numbers in each segment. 
Global size refers to the total defect size in this image. 
AP = apical segment; AS = apical-septal segment; BS 
= basal-septal segment; IL = inferolateral segment; PL 
= posterolateral segment. 
Patients treated with either r-t-PA or a combination of 
rt-PA and coronary angioplasty as well as patients treated 
conventionally were included in our study. This was done 
because it was nor our aim to evaluate the relative efficacy of 
various treatment modalities. Rather, it was our purpose to 
evaluate serial quantitative technetium-99m isonitrile scin- 
tigraphy in relation to infarct-related artery perfusion status, 
regardless of the mode of treatment. Because of the rela- 
tively small number of nonrandomized patients, the conven- 
tional treatment patients should not be considered a control 
group. 
Changes in perfusion defect size were observed both 
Figure 7. Correlation between left ventricular ejection fraction 
(LVEF) at hospital discharge and technetium-99m isonitrile total 
(three view) defect size on the early study (before thrombolysis) and 
on the 18 to 48 hour study (after thrombolysis). 
r--0.83 r--0.76 n: 1 dkt-PA) 
70 I y--0.5x + 58.5 70 r y=-0.5x + 54.0 
10 
t ACUTE lot 18-48 hr 
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early and late after thrombolytic therapy, even if the two 
early studies did not demonstrate any change. One can only 
speculate on the pathophysiologic mechanisms underlying 
these observations. Resolution of no reflow, development of 
collateral flow, changing left ventricular geometry, or reoc- 
elusion of the infarct-related artery may be responsible 
factors. Changes in defect size were also noted in the 
patients who were treated conventionally. This is consistent 
with our serial thallium-201 imaging data in conventionally 
treated patients with acute myocardial infarction; spontane- 
ous changes in thallium-201 defect size occurred in 25% of 
such patients (69). Similar results have been confirmed in 
experimental animal studies (70). 
Finally, the reproducibility of our method of defect quan- 
tijcation should be considered. Inter- and intraoperator 
variability was determined in our laboratory and found to be 
acceptably low. Because of the limited availability of the 
technetium-99m isonitrile, we have no data concerning the 
reproducibility of defect quantification by repeat imaging in 
the same patient. 
Relation to thallium-201 scintigraphy. Although improve- 
ment of the relative distribution of technetium-99m isonitrile 
correlated with restoration of blood flow through the infarct- 
related artery, this does not necessarily imply the presence 
of viable myocardium. Preliminary data (71) in an occlusion- 
reperfusion infarct model indicate that technetium-99m 
isonitrile myocardial uptake after injection during reperfu- 
sion overestimates myocardial blood flow in infarct areas 
with severely reduced flow. 
In an attempt to draw further inferences concerning this 
issue, segmental uptake of technetium-99m isonitrile on the 
last study after thrombolytic therapy was compared with 
segmental uptake of thallium-201 on delayed images after 
exercise. The limitations of fixed thallium-201 defects after 
exercise for predicting irreversibly damaged myocardium 
have recently been recognized (72-76). However, it seems 
reasonable to assume that normal thallium-201 uptake at 
delayed imaging indicates viable myocardium. 
In the present comparative analysis, an overall good 
agreement existed between quantitative segmental distribu- 
tion of both radiopharmaceuticals. In only 12 segments 
(15%), technetium-99m isonitrile uptake quantitatively ex- 
ceeded thallium-201 uptake. In six of these segments tech- 
netium-99m isonitrile uptake was normal, whereas small 
defects were present by thallium-201 imaging. Aside from 
these few segments, overestimation of myocardial blood 
flow did not appear to be a significant problem. Technical 
factors also may account for the discordance. It has been 
suggested that the higher energy photons of technetium-99m 
may obscure small perfusion defects by “shine-through” on 
planar imaging. It is conceivable that rotational tomographic 
imaging would improve the detection of small defects. On 
the other hand, in this limited number of patients, planar 
technetium-99m isonitrile segmental defect size was larger 
than with thallium-201. 
In 11 segments (14%), technetium-99m isonitrile imaging 
revealed a defect, whereas these segments were normal by 
delayed thallium-201 imaging. Six of these segments had a 
reversible exercise-induced thallium-201 defect, whereas the 
remaining segments were also normal after exercise. Al- 
though this discordance could be entirely due to chance in 
comparing two imaging agents under different conditions 
(one at rest. the other after exercise), it is conceivable that 
rest technetium-99m isonitrile perfusion defects, similar to 
thallium-201 perfusion defects, do not always indicate infarc- 
tion, but also can reflect severely reduced myocardial flow. 
The cellular kinetics of technetium-99m isonitrile under 
hypoxic conditions, independent of flow, is at present in- 
completely understood and is an area of active research (48, 
52-55.77). Although some controversy exists, most prelimi- 
nary results suggest no significant inhibitory effect of hy- 
poxia. 
Thus, in this limited number of patients, our findings 
suggest that improved uptake of technetium-99m isonitrile 
after thrombolysis on planar images likely represents viable 
and salvaged myocardium. However, additional studies in- 
volving other metabolic markers of viability are necessary to 
address this issue definitively (78,79). 
Left ventricular function and change in defect size. An 
inverse relation existed between left ventricular ejection 
fraction at hospital discharge and the size of the technetium- 
99m isonitrile myocardial perfusion defect before as well as 
after thrombolytic therapy. The shift of data points to the left 
on the graph (18 to 48 h) (Fig. 7) reflects the decrease in 
defect size after treatment. The predischarge left ventricular 
ejection fraction has been an end point in many clinical trials 
of the efficacy of thrombolytic therapy. However, our data 
showed no significant correlation (r = 0.37) between hospital 
discharge left ventricular ejection fraction and the percent 
change in technetium-99m isonitrile defect size. 
Design of study. The design of the present protocol had 
one significant practical limitation. The second study was 
performed 18 to 48 h after initial scintigraphy. This relatively 
long interval was chosen to avoid possible postreperfusion 
reactive hyperemia (79,80). It is not known whether reactive 
hyperemia after reperfusion in patients with coronary artery 
disease is as significant as it is in an experimental model (81). 
In clinical management, information on the perfusion status 
of the infarct-related artery should be available as soon as 
possible. In the present study, coronary angioplasty was 
performed for clinical or logistic reasons, or both, in 6 of the 
30 patients before the second study was obtained. Taillefer 
et al. (82) and others (83) recently demonstrated the feasi- 
bility of performing stress and rest imaging by two techne- 
tium-99m isonitrile injections (one during exercise and one at 
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rest) on the same day within 4 to 6 h, without loss of 
diagnostic information. We anticipate that with a similar 
approach, it may be feasible to visualize the initial risk zone 
and reperfusion area within a 4 to 6 h time period after 
initiation of treatment. 
Thallium-201 imaging to evaluate thrombolysis. Several 
investigators have explored the use of planar thallium-201 
imaging for predicting infarct-related artery patency and 
evaluating the efficacy of thrombolytic therapy. Markis et al. 
(84) and others (85-87) employed intracoronary administra- 
tion of thallium-201 before and after intracoronary infusion 
of streptokinase. In those studies, new regional uptake of 
thallium-201 after thrombolysis correlated with recovery of 
regional contractile function and, apparently, myocardial 
salvage. However, as Granato et al. (80,88) and Beller (89) 
pointed out in an experimental model, the timing and mode 
of the administration of thallium-201 are important variables 
for interpretation of serial images. If thallium-201 is admin- 
istered too soon after reperfusion, significant hyperemia may 
be present, resulting in excessive uptake on thallium-201 in 
reperfused but necrotic myocardium (90,91). In other clinical 
studies (92-95), thallium-201 was administered intravenously 
and imaging was performed before initiation of thrombolytic 
treatment, followed by delayed redistribution imaging after 
thrombolytic therapy. These studies demonstrated progres- 
sive improvement of myocardial uptake of thallium-201 over 
time in patients with angiographically proved reperfusion of 
the infarct-related artery. Patients who had no reperfusion 
did not show such improvement of thallium-201 uptake. 
The practical problems with thallium-201 imaging before 
initiation of thrombolytic therapy are evident. The need to 
obtain pretreatment images could delay the start of throm- 
bolytic therapy for 230 min, which is clinically and ethically 
unacceptable. On the other hand, if thallium-201 is adminis- 
tered during treatment, in particular after 30 min when 
reperfusion may be in progress, the degree of salvage could 
be overestimated by excessive thallium-201 accumulation in 
areas with hyperemic flow. 
Technetium-99m isonitrile for myocardial imaging. Com- 
pared with technetium-99m isonitrile, thallium-201 has two 
disadvantages in imaging in the setting of acute myocardial 
infarction and thrombolysis. Thallium-201 is not an ideal 
tracer for myocardial imaging because of the relatively low 
energy X-ray emissions and its long physical half-life. Be- 
cause of these physical characteristics, thallium-201 images 
typically are of relatively poor resolution and degraded by 
substantial scatter. Furthermore, the dose administered per 
injection is limited because of dosimetry considerations (96). 
Second, thallium-201 shows the phenomenon of redistribu- 
tion after an intravenous injection. After the initial injection 
and distribution according to myocardial blood flow, myo- 
cardial thallium-201 content will continue to change in areas 
of viable myocardium (9698). 
In contrast, the technetium-99m label of isonitrile has 
photon emissions of 140 keV, which are ideal for gamma 
camera imaging. Therefore, the images are of considerably 
higher quality and demonstrate less scatter (42). Because of 
the relatively short half-life of technetium-99m compared 
with that of thallium-201, a higher dose (30 mCi) can be 
injected. Consequently, counting statistics are better, imag- 
ing time can be relatively short and imaging can be per- 
formed several hours after injection. Furthermore, because 
the isonitrile compound is bound intracellularly (51,55), the 
initial flow-related distribution remains relatively unchanged 
over a prolonged period of time (42,51-54). Because of this 
latter unique characteristic, myocardial uptake of techne- 
tium-99m isonitrile injected intravenously is comparable to a 
certain extent with that of radiolabeled microspheres in- 
jected into the left atrium under experimental conditions 
(99). 
In the present study, initial defect size and defect changes 
were quantitated. To the best of our knowledge, a change in 
size of myocardial perfusion defects in patients undergoing 
thrombolysis thus far has been measured only in a semiquan- 
titative way. Because changes at times may be small and 
subtle, we believe that the quantitation of images is a 
necessity for reproducible and reliable assessment (100). In 
our experience, this method for sizing defects is reproduc- 
ible and objective (61,62). 
Because of the relatively high dose of the radiopharma- 
ceutical administered and the higher 140 keV photon emis- 
sions, technetium-99m isonitrile is an ideal imaging agent for 
single photon tomographic imaging. A subgroup of the 
patients reported here also had tomographic imaging with 
quantification of defect size (101). The serial changes in 
defect size on tomographic slices and the correlation with 
infarct-related artery patency are in agreement with the 
present planar study. Although tomographic imaging using 
an identical imaging protocol as described here for planar 
imaging is feasible, not all patients are in stable enough 
condition for tomographic imaging outside of the coronary 
care unit during the early hours after infarction. In contrast, 
planar imaging is more practical and can be performed in 
virtually all patients at the bedside in the coronary care unit. 
Clearly, direct comparison of the efficacy of planar versus 
tomographic imaging in this circumstance is necessary. 
Clinical implications. This study demonstrates that serial 
planar quantitative technetium-99m isonitrile imaging pro- 
vides a means to define and categorize patients with acute 
infarction undergoing thrombolysis according to initial risk 
area and degree of myocardial perfusion. In clinical trials of 
thrombolytic therapy, these measurements of myocardial 
perfusion may allow for better categorization of patients. In 
addition, in individual patients, it may allow an assessment 
of the success of initial reperfusion, which may aid in 
planning further therapeutic strategies. 
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